Briakinumab
Briakinumab
Briakinumab (pronounced as bry-uh-KIN-yoo-mab) is a monoclonal antibody designed for the treatment of autoimmune diseases. It was developed by Abbott Laboratories.
Etymology
The name "Briakinumab" is derived from the Greek words "briakos" meaning "small" and "numab" meaning "antibody". The prefix "briak-" refers to the small size of the molecule, while "-numab" is a common suffix for monoclonal antibodies.
Usage
Briakinumab was primarily developed for the treatment of psoriasis, a chronic skin condition. It works by targeting and neutralizing interleukin 12 and interleukin 23, two proteins that are believed to play a key role in the development of psoriasis.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Autoimmune diseases: Diseases in which the body's immune system attacks healthy cells.
- Psoriasis: A chronic skin condition that causes cells to build up rapidly on the surface of the skin.
- Interleukin 12: A type of protein that plays a crucial role in the activities of white blood cells.
- Interleukin 23: A type of protein that is involved in inflammatory responses.
See Also
External links
- Medical encyclopedia article on Briakinumab
- Wikipedia's article - Briakinumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski